Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Do poor-responder patients undergoing IVF benefit from splitting and increasing the daily gonadotropin dose?

Ezra O, Haas J, Nahum R, Maman E, Cohen Y, Segev-Zahav A, Orvieto R.

Gynecol Endocrinol. 2019 Apr 29:1-4. doi: 10.1080/09513590.2019.1608520. [Epub ahead of print]

PMID:
31032673
2.

Can sonographic measurements and changes in cervical length during pregnancy predict preterm labour in an asymptomatic low-risk population?

Weitzner O, Biron-Shental T, Daykan Y, Ezra O, Markovitch O.

J Matern Fetal Neonatal Med. 2019 Jul;32(13):2107-2112. doi: 10.1080/14767058.2018.1425990. Epub 2018 Jan 18.

PMID:
29310480
3.

Patient-Specific Tailored Intervention Improves INR Time in Therapeutic Range and INR Variability in Heart Failure Patients.

Gotsman I, Ezra O, Hirsh Raccah B, Admon D, Lotan C, Dekeyser Ganz F.

Am J Med. 2017 Aug;130(8):982-989. doi: 10.1016/j.amjmed.2017.02.030. Epub 2017 Mar 24.

PMID:
28344144
4.

p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity.

Molchadsky A, Ezra O, Amendola PG, Krantz D, Kogan-Sakin I, Buganim Y, Rivlin N, Goldfinger N, Folgiero V, Falcioni R, Sarig R, Rotter V.

Cell Death Differ. 2013 May;20(5):774-83. doi: 10.1038/cdd.2013.9. Epub 2013 Feb 15.

5.

Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53.

Goldstein I, Rivlin N, Shoshana OY, Ezra O, Madar S, Goldfinger N, Rotter V.

Carcinogenesis. 2013 Jan;34(1):190-8. doi: 10.1093/carcin/bgs318. Epub 2012 Oct 10.

PMID:
23054612
6.

p53, a novel regulator of lipid metabolism pathways.

Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, Rotter V.

J Hepatol. 2012 Mar;56(3):656-62. doi: 10.1016/j.jhep.2011.08.022. Epub 2011 Oct 26.

PMID:
22037227
7.

Ethical dilemmas in antibiotic treatment.

Leibovici L, Paul M, Ezra O.

J Antimicrob Chemother. 2012 Jan;67(1):12-6. doi: 10.1093/jac/dkr425. Epub 2011 Oct 6. Review.

PMID:
21980065
8.

Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.

Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, Molchadsky A, Goldfinger N, Brenner O, Rotter V.

J Exp Med. 2010 Sep 27;207(10):2127-40. doi: 10.1084/jem.20100797. Epub 2010 Aug 9.

9.

Modulated expression of WFDC1 during carcinogenesis and cellular senescence.

Madar S, Brosh R, Buganim Y, Ezra O, Goldstein I, Solomon H, Kogan I, Goldfinger N, Klocker H, Rotter V.

Carcinogenesis. 2009 Jan;30(1):20-7. doi: 10.1093/carcin/bgn232. Epub 2008 Oct 8.

Supplemental Content

Support Center